<DOC>
	<DOCNO>NCT02877225</DOCNO>
	<brief_summary>The purpose study demonstrate bioequivalence ( BE ) new formulation ibrutinib market Imbruvica formulation healthy adult fast condition .</brief_summary>
	<brief_title>Study Assess Bioequivalence Ibrutinib 140 Milligram ( mg ) Tablet 140 mg IMBRUVICA Capsule</brief_title>
	<detailed_description />
	<criteria>Be man woman 18 55 year age , inclusive , screen If woman , must negative serum beta human chorionic gonadotropin ( Beta hCG ) pregnancy test screen Day 1 treatment period Body Mass Index ( BMI ) ; weight [ kilogram ( kg ) ] /height^2 [ meter ( ) ^2 ) ] 18.0 30.0 kg/m2 ( inclusive ) body weight less 50 kg screen If woman , must nonchildbearing potential , define either : ) Postmenopausal : A postmenopausal state define menses least 12 month without alternative medical cause serum follicle stimulate hormone ( FSH ) level postmenopausal range ( great ( &gt; ) 40 International Units Per Liter ( IU/L ) milliinternational unit per milliliter ( mIU/mL ) , OR , b ) Permanently sterile : Permanent sterilization method include subtotal total hysterectomy , bilateral salpingectomy , bilateral tubal occlusion/ligation procedure ( without reversal operation ) , bilateral oophorectomy , transcervical sterilization Blood pressure ( supine least 5 minute rest ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic screen Alanine aminotransferase , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) total bilirubin equal low upper limit normal ( per National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events [ CTCAE ] ) screen History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness Investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology biochemistry screening deem appropriate Investigator Clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram ( ECG ) screening deem appropriate Investigator History clinically significant allergy , especially know hypersensitivity intolerance sulfonamide betalactam antibiotic Positive test hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) antibodies screen Positive test human immunodeficiency virus type 1 ( HIV1 ) HIV2 antibodies screen Received investigational drug ( include investigational vaccine ) use invasive investigational medical device within 1 month within period le 10 time drug 's halflife , whichever longer , plan first intake study drug History clinically significant allergy , especially know hypersensitivity intolerance sulfonamide betalactam antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>